An N-glycosylation hotspot in immunoglobulin κ light chains is associated with AL amyloidosis

被引:0
|
作者
Alice Nevone
Maria Girelli
Silvia Mangiacavalli
Bruno Paiva
Paolo Milani
Pasquale Cascino
Maggie Piscitelli
Valentina Speranzini
Claudio Salvatore Cartia
Pietro Benvenuti
Ibai Goicoechea
Francesca Fazio
Marco Basset
Andrea Foli
Martina Nanci
Giulia Mazzini
Serena Caminito
Melania Antonietta Sesta
Simona Casarini
Paola Rognoni
Francesca Lavatelli
Maria Teresa Petrucci
Pier Paolo Olimpieri
Stefano Ricagno
Luca Arcaini
Giampaolo Merlini
Giovanni Palladini
Mario Nuvolone
机构
[1] University of Pavia,Department of Molecular Medicine
[2] Fondazione IRCCS Policlinico San Matteo,Amyloidosis Research and Treatment Center
[3] Fondazione IRCCS Policlinico San Matteo,Division of Hematology
[4] Instituto de Investigacion Sanitaria de Navarra (IDISNA),Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), CIBER
[5] Università Degli Studi di Milano,ONC number CB16/12/00369
[6] Sapienza University of Rome,Dipartimento di Bioscienze
[7] Sapienza University of Rome,Hematology, Department of Translational and Precision Medicine, Azienda Ospedaliera Policlinico Umberto I
[8] IRCCS Policlinico San Donato,Department of Public Health and Infectious Diseases
来源
Leukemia | 2022年 / 36卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Immunoglobulin light chain (AL) amyloidosis is caused by a small, minimally proliferating B-cell/plasma-cell clone secreting a patient-unique, aggregation-prone, toxic light chain (LC). The pathogenicity of LCs is encrypted in their sequence, yet molecular determinants of amyloidogenesis are poorly understood. Higher rates of N-glycosylation among clonal κ LCs from patients with AL amyloidosis compared to other monoclonal gammopathies indicate that this post-translational modification is associated with a higher risk of developing AL amyloidosis. Here, we exploited LC sequence information from previously published amyloidogenic and control clonal LCs and from a series of 220 patients with AL amyloidosis or multiple myeloma followed at our Institutions to define sequence and spatial features of N-glycosylation, combining bioinformatics, biochemical, proteomics, structural and genetic analyses. We found peculiar sequence and spatial pattern of N-glycosylation in amyloidogenic κ LCs, with most of the N-glycosylation sites laying in the framework region 3, particularly within the E strand, and consisting mainly of the NFT sequon, setting them apart with respect to non-amyloidogenic clonal LCs. Our data further support a potential role of N-glycosylation in determining the pathogenic behavior of a subset of amyloidogenic LCs and may help refine current N-glycosylation-based prognostic assessments for patients with monoclonal gammopathies.
引用
收藏
页码:2076 / 2085
页数:9
相关论文
共 50 条
  • [41] Periodic Changes in the N-Glycosylation of Immunoglobulin G During the Menstrual Cycle
    Juric, Julija
    Peng, Hongli
    Song, Manshu
    Vuckovic, Frano
    Simunovic, Jelena
    Trbojevi-Akmacic, Irena
    Wang, Youxin
    Liu, Jiaonan
    Gao, Qing
    Wang, Hao
    Chu, Qiaoyun
    Pezer, Marija
    Wang, Wei
    Lauc, Gordan
    ENGINEERING, 2023, 26 : 108 - 118
  • [42] Genetic control of population diversity in human immunoglobulin G N-glycosylation
    Soplenkova, Anna
    Maslov, Denis
    Timoshchuk, Anna
    Spector, Tim
    Georges, Michel
    Sharapov, Sodbo
    Lauc, Gordan
    Aulchenko, Yury
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2024, 32 : 1172 - 1173
  • [43] Site-Specific N-Glycosylation Analysis of Human Immunoglobulin E
    Plomp, Rosina
    Hensbergen, Paul J.
    Rombouts, Yoann
    Zauner, Gerhild
    Dragan, Irina
    Koeleman, Carolien A. M.
    Deelder, Andre M.
    Wuhrer, Manfred
    JOURNAL OF PROTEOME RESEARCH, 2014, 13 (02) : 536 - 546
  • [44] Immunoglobulin G Fc N-glycosylation in Guillain-Barre syndrome treated with intravenous immunoglobulin
    Fokkink, W. -J. R.
    Selman, M. H. C.
    Wuhrer, M.
    Jacobs, B. C.
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2014, 178 : 105 - 107
  • [45] N-glycosylation of monoclonal light chains on routine MASS-FIX testing is a risk factor for MGUS progression
    Angela Dispenzieri
    D. R. Larson
    S. V. Rajkumar
    R. A. Kyle
    S. K. Kumar
    Taxiarchis Kourelis
    Bonnie Arendt
    Maria Willrcih
    Surendra Dasari
    David Murray
    Leukemia, 2020, 34 : 2749 - 2753
  • [46] N-glycosylation of monoclonal light chains on routine MASS-FIX testing is a risk factor for MGUS progression
    Dispenzieri, Angela
    Larson, D. R.
    Rajkumar, S. V.
    Kyle, R. A.
    Kumar, S. K.
    Kourelis, Taxiarchis
    Arendt, Bonnie
    Willrcih, Maria
    Dasari, Surendra
    Murray, David
    LEUKEMIA, 2020, 34 (10) : 2749 - 2753
  • [47] Treatment of Immunoglobulin Light Chain (Primary or AL) Amyloidosis
    Gertz, Morie A.
    Buadi, Francis K.
    Hayman, Suzanne R.
    ONCOLOGY-NEW YORK, 2011, 25 (07): : 620 - 626
  • [48] Acquired potential N-glycosylation sites within the tumor-specific immunoglobulin heavy chains of B-cell malignancies
    Zabalegui, N
    de Cerio, ALD
    Inogés, S
    Rodriguez-Calvillo, M
    Pérez-Calvo, J
    Hernández, M
    García-Foncillas, J
    Martín-Algarra, S
    Rocha, E
    Bendandi, M
    HAEMATOLOGICA, 2004, 89 (05) : 541 - 546
  • [49] Serum and Plasma Immunoglobulin G Fc N-Glycosylation Is Stable during Storage
    Amez Martin, Manuela
    Wuhrer, Manfred
    Falck, David
    JOURNAL OF PROTEOME RESEARCH, 2021, 20 (05) : 2935 - 2941
  • [50] Structural relationship of λ-type light chains with AL amyloidosis
    Alim, MA
    Yamaki, S
    Hossain, MS
    Takeda, K
    Yamagata, F
    Takashi, I
    Shinoda, T
    CLINICAL IMMUNOLOGY, 1999, 90 (03) : 399 - 403